Form 4: REGENXBIO Director Argeris Karabelas Executes Option and Sells Shares Under 10b5-1 Plan

Argeris Karabelas, a director at REGENXBIO Inc., exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan on September 3, 2024.

Summary

• On September 3, 2024, Argeris Karabelas, a director of REGENXBIO Inc., executed stock options to acquire 10,000 shares of common stock at a price of $3.76 per share.
• Simultaneously, Karabelas sold 9,300 shares at a weighted average price of $11.50, with individual trades ranging from $11.24 to $12.20.
• An additional 700 shares were sold at a weighted average price of $12.34, with individual trades ranging from $12.24 to $12.53.
• Following these transactions, Karabelas directly owns 11,286 shares of REGENXBIO common stock and holds options for 10,000 shares.

Sentiment

Score: 5

Explanation: Neutral sentiment as the transactions were executed under a pre-arranged 10b5-1 trading plan. It doesn't necessarily reflect a positive or negative view of the company's prospects.

Positives

• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, suggesting they were planned in advance and not based on insider information.

Risks

• Director selling activity could be perceived negatively by investors, potentially impacting the stock price.

Industry Context

Insider transactions are routinely monitored by investors as they can provide insights into management's perspective on the company's valuation and future prospects. However, transactions under 10b5-1 plans are less indicative of current sentiment.

Stakeholder Impact

• Shareholders may react to the insider selling activity, potentially influencing the stock price.

Key Dates